R&D to Revenue
19.01%
Fiscal year · Period ending:

RPRX R&D to Revenue
What is r&d to revenue?
R&D spending as percentage of revenue.
RPRX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 19.006% | |
| 0.0884% | |
| 2.2085% | |
| 7.9164% | |
| 8.7393% | |
| 1.2387% | |
| 4.5769% | |
| 21.8737% | |
| 7.3762% | |
| 4.8482% | |
| 5.9538% |
Frequently asked questions: RPRX r&d to revenue
What is Royalty Pharma plc (RPRX)'s current r&d to revenue?
Royalty Pharma plc (RPRX)'s latest reported r&d to revenue (Fiscal year) is 19.01% as of Dec 31, 2025. R&D spending as percentage of revenue.
How much historical r&d to revenue data is available for RPRX?
Stock Alarm Pro provides 11 dated annual fiscal periods observations for Royalty Pharma plc (RPRX)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.
How can I compare RPRX's r&d to revenue to peers or set an alert?
You can open RPRX's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on RPRX delivered by push, email, or phone call.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance